An Open-Label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of H1337 Ophthalmic Solution, 1% in Healthy Volunteers
Latest Information Update: 19 Feb 2025
At a glance
- Drugs H 1337 (Primary)
- Indications Glaucoma; Ocular hypertension; Pulmonary hypertension
- Focus Adverse reactions
- Sponsors D. Western Therapeutics Institute
- 14 Oct 2024 Status changed from recruiting to completed.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 29 Aug 2024 New trial record